RUNX2 and leukemia: These studies and our current findings combined indicate a potential overlapping or compensatory role for ETS factors in the regulation of MEIS1. From a therapeutic perspective, it has been shown that mithramycin (plicamycin) inhibits the binding of ERG and FLI1 to DNA in the context of RUNX2, providing a potential new therapeutic avenue for ETS TF driven leukemias [44].